Chronic Myeloid Leukemia with e19a2 BCR-ABL1 Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring. (2nd July 2012)

• Record Type: Journal Article
• Authors: Langabeer, Stephen E.; McCarron, Sarah L.; Kelly, Johanna; Krawczyk, Janusz; McPherson, Suzanne; Perera, Kanthi; Murphy, Philip T.
• Other Names: Dasgupta U. Academic Editor.; Imai C. Academic Editor.
• Is Part Of: Case reports in hematology. Volume 2012(2012)
• Publication Date: 2012-07-02
• Subjects: Hematology -- Periodicals; Hematology -- Case studies -- Periodicals; Blood -- Diseases -- Periodicals; Hematology; Hematologic Diseases; Blood -- Diseases; Hematology; Electronic journals; Periodicals; Case studies; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; 616.15
• DOI: 10.1155/2012/458716
• Languages: English
• ISSNs: 2090-6560

Abstract

Abstract : While most patients with chronic myeloid leukemia (CML) express either e13a2 or e14a2 BCR-ABL1 transcripts, a significant minority expresses variant transcripts, of which e19a2 is the most common. Although considered to have a relatively favourable outcome, reported responses to tyrosine kinase inhibitor (TKI) therapy are variable with molecular monitoring in CML patients with e19a2 BCR-ABL1 transcripts rarely reported. A case of e19a2 BCR-ABL1 CML with marked thrombocytosis is described in which the value of molecular monitoring is emphasised during treatment interruptions, dose reductions, and changes. This case serves to demonstrate the requirement for prospective real-time quantitative PCR (RQ-PCR) assays for patients with variant BCR-ABL1 transcript types and standardisation of such assays to enable modern patient management.